An interventional study of Transcatheter mitral valve edge-to-edge repair (M-TEER) in Mitral Regurgitation, Valvular Heart Disease and Heart Failure, sponsored by LMU Klinikum. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-09.
Sponsored by LMU Klinikum · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 81 studies in Mitral Valve Insufficiency with a site in Germany — 24 open to participants now, 32 under way, none of them phase 3. Mitral Valve Insufficiency · Germany.
Among the 81 studies in Mitral Valve Insufficiency with a site in Germany, this one is the 17th largest by planned enrollment of the 48 interventional ones that give a count, is one of 4 that started in 2024, is one of 39 with no phase, reaches primary completion later than 15 of the 31 other live ones, and was the 73rd registered.
471 studies on the registry are indexed under Mitral Valve Insufficiency; 165 are open to participants now.
Browse Mitral Valve Insufficiency studies →24 of the 81 studies in Mitral Valve Insufficiency with a site in Germany are open now. Recruiting first, the newest first:
University Medical Center Mainz · Sites in Germany
Ages 18+
Jena University Hospital · Sites in Germany
Ages 18+
Medical University of Vienna · Sites in Germany, Austria, Italy and 1 more country
Ages 18+
4C Medical Technologies, Inc. · Sites in Germany, United States, Canada and 4 more countries
Ages 18+
Hangzhou Valgen Medtech Co., Ltd · Sites in Germany
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 121 Mitral Valve Insufficiency studies recruiting now, 100 (83%) set no upper age limit and 6 (5%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
81 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 4 3
First in 2006; this study’s year is marked. 4 started in 2024.
This study's planned enrollment of 180 is above the median of 69 across 280 interventional studies indexed under Mitral Valve Insufficiency.
Median enrollment 113 across the 48 interventional studies, 214 across the 33 observational. Of the 37 that completed or were terminated, 12 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
48 of 81 have an industry lead sponsor. The 10 most frequent:
LMU Klinikum is the lead sponsor of 53 studies on the registry; 20 are open to participants now.
LMU Klinikum has 3 studies filed under Mitral Valve Insufficiency — fewer than ten, so there is no comparison to draw.
4 of the studies in Mitral Valve Insufficiency with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04029363HighLife SASExpanded Study of the HighLife 28mm Trans-septal Trans-catheter Mitral Valve in Patients With Moderate-severe or Severe Mitral Regurgitation and at High Surgical Risk | 2026-12-15 |
| NCT03339115Cardiovalve Ltd.AHEAD: European Feasibility Study of the Cardiovalve Transfemoral Mitral Valve System | 2026-12-31 |
| NCT04898335LMU KlinikumTendyne European Experience Registry | 2026-12-31 |
| NCT06634121LMU KlinikumEfficacy of MitraCLip Vs. PASCAL for the TrEAtment of MitraL REgurgiTation in an All-comer Population | 2027-04-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 81 studies in Mitral Valve Insufficiency with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To investigate potential differences in procedural outcomes of both commercially available transcatheter edge-to-edge mitral valve repair devices in a non-selected clinical setting.
In the context of M-TEER, two different systems (MitraClip vs. PASCAL) are CE certified and clinically available. In the case of non-complex anatomy, both systems are comparable in terms of effectiveness. Whether this holds true in cases of complex or highly complex anatomy in an "Allcomer patient population" is currently unclear.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Device: Transcatheter mitral valve edge-to-edge repair (M-TEER)
Device: Transcatheter mitral valve edge-to-edge repair (M-TEER)
M-TEER is performed via a transfemoral venous approach. After puncture of the interatrial septum the mitral valve is repaired using either the PASCAL or MitraClip device.
Postprocedural residual MR measured by 3D EROA
residual MR measured by 3D EROA as continuous parameter
Time frame: During the index procedure
Reduction in MR EROA
Reduction in MR EROA from baseline to postprocedural (relative and absolut value)
Time frame: During the index procedure
Comparing EROA in complex vs. non-complex patients
Evaluation according to EROA reduction
Time frame: During the index procedure
Postprocedural MV opening area
Postprocedural MV opening area (planimetric)
Time frame: During the index procedure
Postprocedural MV inflow gradient
Mean pressure gradient and pressure halftime
Time frame: During the index procedure
SLDA
Single Leaflet Device Attachment
Time frame: During the index procedure, at 30-day follow-up and at 1-year follow-up
Conversion to surgery or re-imaging of the MV
Conversion to surgery (urgently or elective) or re-imaging of the MV
Time frame: During the index procedure, at 30-day follow-up and at 1-year follow-up
Stratification by MR etiology
Primary vs. Secondary MR
Time frame: During the index procedure, at 30-day follow-up and at 1-year follow-up
Combined endpoint of mortality, repeat MV intervention or HHF
Assessed at 30-days and 1-year
Time frame: During the index procedure, at 30-day follow-up and at 1-year follow-up
Quality of Life
Measured using the KCCQ Score
Time frame: At 30-day follow-up and at 1-year follow-up
Exertional dyspnea
NYHA functional class
Time frame: At 30-day follow-up and at 1-year follow-up
Plan to share: Undecided
No publications or documents are linked to this record.
Started Apr 2024 (actual). Primary completion is estimated for Apr 2027, 36 months after the start.
Of 144 interventional studies with no phase under Mitral Valve Insufficiency, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 108. This study's planned 36 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
LMU Klinikum